Education and Training
Study to Evaluate the Safety and Tolerability of CC-94676 in Participants With Metastatic Castration-Resistant Prostate Cancer
The purpose of this study is to assess the safety, tolerability and preliminary efficacy of CC-94676 in men with progressive metastatic castration resistant prostate cancer.
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- drug: CC-94676
- drug: CC1083611
- drug: CC1083610
Eligibility
Inclusion Criteria:
- Must have histologically or cytologically confirmed adenocarcinoma of the prostate
- Progressed on androgen deprivation therapy (ADT) and at least one prior secondary
hormonal therapy approved for castration-resistant prostate cancer (CRPC)
- Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1
Exclusion Criteria:
- Prior treatment with an androgen receptor (AR) degrader
- Concurrent malignancy (present during screening) requiring treatment or history of
prior malignancy active within 1 year prior to the first dose of IP
- Clinically significant venous thromboembolism within 3 months prior to the first dose
of IP
- Any significant medical condition, such as uncontrolled infection, laboratory
abnormality, or psychiatric illness
Other protocol-defined inclusion/exclusion criteria apply
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study
Male
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Aidan Keil O'Brien
650-723-3046
I'm interested